The revenue numbers in this article have been corrected from those reported earlier today.
NEW YORK, Feb. 10 (GenomeWeb News) - Sequenom today reported total reported that fourth-quarter revenues fell 24 percent to $6.1 million from $8 million for the year-ago quarter.
The company spent $3.9 million on R&D for the quarter, down from $6.4 million in the year-ago period.
The company cut its net loss to $6.9 million from $10.1 million for the fourth quarter of 2003, a 32-percent improvement for the San Diego-based company.
Sequenom reported cash and cash equivalents of $38 million as of
Looking ahead, Sequenom said in 2005 it plans to launch a product with "enhanced multiplexing levels and advanced gene expression software," and release its first analyte specific reagents for public-domain genetic tests such as Factor V and cystic fibrosis.
Sequenom yesterday announced the resignation of CEO Toni Schuh.